20431 ⎘
Medicinal preparations containing organic active ingredients; Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring heteroatoms, e.g. piperazine; Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
SPIROMACROCYCLIC OREXIN 2 RECEPTOR AGONISTS
#22-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE AND 7-AMINO-1-PYRIMIDO[4,5-D]PYRIMIDIN-2(1 H)-ONE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER
#3MACROCYCLIC PYRIMIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF NEURODEGENERATIVE DISEASE CONTAINING SAME AS ACTIVE INGREDIENT
#4METHODS TO STRENGTHEN VISUAL PATHWAYS
#5Use of a Janus Kinase Inhibitor and a Telomerase Inhibitor for the Treatment of Myeloproliferative Neoplasms
#6INDAZOLE MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE
#7Neurotrophic Receptor Tyrosine Kinase (NTRK) Inhibitors and Methods Using Same
#8MACROCYCLIC IMIDAZO [1,2-B] PYRIDAZINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF
#9Uses of JAK Inhibitors in the Management of Inflammation-Associated Depression and Central Nervous System (CNS) Pathologies
#10INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE, COMPOSITIONS, AND METHODS OF USE
#11NOVEL COMPOUND AS NADPH OXIDASE 2 INHIBITOR AND PHARMACEUTICAL COMPOSITION CONTAINING SAME
#12Treatment or Reversal of Treatment Resistant Depression and Related Central Nervous System (CNS) Inflammatory Conditions with a JAK Inhibitor
#13HETEROARYL DERIVATIVE COMPOUND AND USES THEREOF
#14MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR
#15INHIBITORS OF KIF18A AND USES THEREOF
#16METHODS OF TREATING FLT3-MUTATED HEMATOLOGIC CANCERS
#17COMPOSITIONS COMPRISING MODIFIED PHOSPHOLIPIDS AND USES THEREOF
#18MACROCYCLES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF
#19TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS
#20TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS
#21THERAPEUTIC USES OF MACROCYCLIC COMPOUNDS
#22METHODS FOR TREATING HAIR LOSS AND NAIL BRITTLENESS, FRAGILITY, OR PITTING
#23EXOSOMAL COMPOSITIONS INCLUDING ANESTHETICS
#24METHODS OF TREATMENT FOR CYSTIC FIBROSIS
#25QUINOLINE COMPOUND AND USE THEREOF
#26TYK2 INHIBITORS AND USES THEREOF
#27DIHYDROIMIDAZO-PYRIMIDINONE COMPOUNDS AS LP-PLA2 INHIBITORS AND USE THEREOF
#28MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR
#29COMPOSITIONS COMPRISING MODIFIED PHOSPHOLIPIDS AND USES THEREOF
#30Inhibition Of Rip Kinases For Treating Neurodegenerative Disorders
#31METHODS FOR TREATING HAIR LOSS DISORDERS
#32COVALENT EGFR INHIBITORS AND METHODS OF USE THEREOF
#33MACROCYCLIC GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONISTS
#34NOVEL MACROCYCLIC AMINOPYRAZOLE COMPOUNDS AS CDK2 INHIBITORS
#35POLYMORPHIC FORM OF TG02 FOR TREATING CANCER
#36POLYMORPHIC FORM OF TG02 FOR TREATING CANCER
#37RIPK1 INHIBITORS AND METHODS OF USE
#38Cyclic Pyridine Derivatives as cGAS Inhibitors
#39TREATMENT OF CANCER WITH TG02
#40MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR
#41TYPE I DIABETES THERAPY
#42SYSTEMS, DEVICES, AND METHODS FOR TREATING A PULMONARY DISORDER WITH AN AGENT
#43MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR
#44MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR
#45HIGHLY ACTIVE ANTI-NEOPLASTIC AND ANTI-PROLIFERATIVE AGENTS
#46TARGETED THERAPY FOR THE TREATMENT & PREVENTION OF LIFE-THREATENING COMPLICATIONS OF INFECTION
#47ANTIMALARIAL AGENTS
#48Methods for treating hair loss disorders
#49MACROCYCLIC ULK1/2 INHIBITORS
#50MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR
#51SYSTEMS, DEVICES, AND METHODS FOR TREATING A PULMONARY DISORDER WITH AN AGENT
#52Methods for treating hair loss disorders
#53MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR
#54LIPID PRODRUGS OF JAK INHIBITORS AND USES THEREOF
#55METHODS FOR TREATING INFECTIOUS DISEASES
#56METHODS OF TREATING FLT3-MUTATED HEMATOLOGIC CANCERS
#57INHIBITION OF RIP KINASES FOR TREATING NEURODEGENERATIVE DISORDERS
#58COMPOSITIONS WITH SYNERGISTIC PERMEATION ENHANCERS FOR DRUG DELIVERY
#59USE OF A JANUS KINASE INHIBITOR AND A TELOMERASE INHIBITOR FOR THE TREATMENT OF MYELOPROLIFERATIVE NEOPLASMS
#60Use of sodium channel blockers for the treatment of neuropathic pain developing as a consequence of chemotherapy
#61TOPICAL COMPOSITIONS FOR STIMULATING HAIR GROWTH
#62TREATING DISEASES VIA TARGETED MODULATION OF GENE SIGNALING NETWORKS
#63METHODS OF TREATING TRANSPLANT REJECTION
#64Substituted 1,4-methanopyrido[1′,2′:4,5]pyrazino[1,2-a]pyrimidines for treating viral infections
#65Pyrazolopyrimidine derivative and use thereof
#66Type I diabetes therapy
#67HIGHLY ACTIVE ANTI-NEOPLASTIC AND ANTI-PROLIFERATIVE AGENTS
#68Treatment of cancer with TG02
#69Polymorphic form of TG02 for treating cancer
#70Methods for treating hair loss disorders
#71Methods for treating hair loss disorders
#72Use of sodium channel blockers for the treatment of neuropathic pain developing as a consequence of chemotherapy
#73Macrocyclic compounds as ROS1 kinase inhibitors
#74Highly active anti-neoplastic and anti-proliferative agents
#75Substituted 3,4,5,6,8,10,14,14a-octahydro-2h-2,6-methanopyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazocines and methods for treating viral infections
#76Macrocylic compounds as ROS1 kinase inhibitors
#77MACROCYCLIC COMPOUNDS AS ROS1 KINASE INHIBITORS
#78Polymorphic form of TG02
#79METHODS OF TREATING TRANSPLANT REJECTION
#80Methods and devices for renal nerve blocking
#81COMBINATION OF LBH589 WITH OTHER THERAPEUTIC AGENTS FOR TREATING CANCER
#82Modified macrocyclic compounds
#83Compounds and methods for the targeted degradation of fetal liver kinase polypeptides
#84Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor and/or a JAK-2 Inhibitor
#85Heterocyclic compounds and their use in preventing or treating bacterial infections
#86COMBINATION OF LBH589 WITH OTHER THERAPEUTIC AGENTS FOR TREATING CANCER
#87Methods for treating hair loss disorders
#88HIGHLY ACTIVE ANTI-NEOPLASTIC AND ANTI-PROLIFERATIVE AGENTS
#89Substituted 2,3,4,5,7,9,13,13a-octahydro-1,5-methanopyrido[1′,2′:4,5]pyrazino[1,2-a][1,3]diazepines and methods for treating viral infections
#90COMBINATION OF LBH589 WITH OTHER THERAPEUTIC AGENTS FOR TREATING CANCER
#91Therapeutic uses of selected pyrrolopyrimidine compounds with anti-mer tyrosine kinase activity
#92Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor and/or a JAK-2 inhibitor
#93Macrocyclic compounds as Trk kinase inhibitors
#94Methods to treat visual impairment
#95MACROCYCLIC COMPOUNDS AS ALK, FAK AND JAK2 INHIBITORS
#96Imidazopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication
#97Use of sodium channel blockers for the treatment of neuropathic pain developing as a consequence of chemotherapy
#98Methods for treating hair loss disorders
#99Methods for treating hair loss disorders
#100Pyridazinone compounds and uses thereof
#101Methods and devices for renal nerve blocking
#102Methods for treating hair loss disorders
#103Methods for treating hair loss disorders
#104Inhibitors of human immunodeficiency virus replication
#105Inhibitors of human immunodeficiency virus replication
#106Nitrogen containing compounds
#107Nitrogen containing compounds
#108COMBINATION OF LBH589 WITH OTHER THERAPEUTIC AGENTS FOR TREATING CANCER
#109Nitrogen containing compounds
#110Compositions and methods for obtaining cells to treat heart tissue
#111Methods for Treating Osteoarthritis
#112Substituted 2,3,4,5,7,9,13,13a-octahydropyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazepines and methods for treating viral infections
#1131,6-diazabicyclo [3,2,1] octan-7-one derivatives and their use in the treatment of bacterial infections
#114Tricyclic heterocycles useful as dipeptidyl peptidase-IV inhibitors
#115Drug targets to overcome de novo drug-resistance in multiple myeloma
#116COMBINATION OF LBH589 WITH OTHER THERAPEUTIC AGENTS FOR TREATING CANCER
#117PHARMACEUTICAL COMPOSITIONS FOR THE STIMULATION OF STEM CELLS
#118Method for treating osteoarthritis
#119Stable pharmaceutical composition of freeze-dried tetrodotoxin powder
#120PROLONGED DURATION LOCAL ANESTHESIA WITH MINIMAL TOXICITY
#121Nuclear export inhibitors of topoisomerase II alpha
#122Organic compounds
#123FREEZE-DRIED REPARATION OF TETRODOTOXIN AND THE PRODUCING METHOD THEREOF
#124Compositions and methods for obtaining cells to treat heart tissue
#125Methods for treating osteoarthritis
#126Stable pharmaceutical composition of freeze-dried tetrodoxin powder
#127Use of sodium channel blockers for the treatment of neuropathic pain developing as a consequence of chemotherapy
#128COMBINATION OF LBH589 WITH OTHER THERAPEUTIC AGENTS FOR TREATING CANCER
#129Use of sodium channel blockers for the management of musculoskeletal pain
#130Kinase modulating compounds and uses thereof for treatment of cancer
#131METHODS AND DEVICES FOR RENAL NERVE BLOCKING
#132Method for treating osteoarthritis
#133METHODS FOR ENHANCING WOUND HEALING
#134Solid orally ingestible formulations of tetrodotoxin
#135Methods for enhancing wound healing
#136Use of botulinum toxin therapy for treatment of recalcitrant voiding dysfunction
#137Stable pharmaceutical composition of freeze-dried tetrodotoxin powder